No products
Product successfully added to your shopping cart
There are 0 items in your cart. There is 1 item in your cart.
View larger
Enkephinex-OA 99% Enkephalinase Inhibitor (ENKi)
Enkephinex-OA is an enkephalinase inhibitor with modest oral potency and efficacious BBB penetration. An analogue of RB-120 it demonstrates robust efficacy within in vivo models for analgesic, antidepressant, and anxiolytic paradigms.
Research Indications: Analgesic Research, Anti-Addiction Research, Antidepressant Research, Anxiolytic Research.
Pre-Order Due Early April - Buy 2 Get 1 Free Pre-Order Special
More info
Enkephinex-OA is an enkephalinase inhibitor with modest oral potency and efficacious BBB penetration. An analogue of RB-120 it demonstrates robust efficacy within in vivo models for analgesic, antidepressant, and anxiolytic paradigms.
Animal Model Pharmacokinetics:
Animal model (mice) pharmacokinetic studies demonstrates strong BBB penetration with very modest oral bioavailability.
Half-Life: Approximately 3.8 hours
Potential Human Use Protocols and Projections:
Within extrapolations from in vivo animal models projected dose arms for clinical trial are at 250mg, 500mg, and 1000mg b.i.d. that would be applicable for antidepressant and analgesic/analgesic-sparing trials. Addiction cessation is another potential target goal.
Though Enkephinex-OA demonstrates some modest oral bioavailability efficacy would appear to be far superior within sublingual administration. Efficacious dosages for sublingual administration are projected at 15mg to 60mg.
Format of Supply: 60mg/ml in ethanol
USAGE: For Research Use Only! Not For Use in Humans.